Insight

Bernard A. Fox: Introducing M3T01 – Novel Drug Developed by Matthew Taylor and His Team

Bernard A. Fox and Matthew Taylor

Aug 5, 2025, 12:06

Bernard A. Fox: Introducing M3T01 – Novel Drug Developed by Matthew Taylor and His Team

Bernard A. Fox, Co-founder, President and CEO of UbiVac, shared a post by Earle A. Chiles Research Institute on LinkedIn, adding:

“Great to see this novel drug, developed by my colleague, Matthew Taylor MD and his team at the Earle A. Chiles Research Institute and Straterx, being administered to patients! This drug should support maintenance of a patient’s cancer killer cells and might become an essential component of combination immunotherapy strategies for patients with cancer.

This new drug has promise to improve efficacy of treatment with checkpoint blockers (eg pembrolizumab, nivolumab, retifanlimab), Adoptive immunotherapy (TIL, TCR-gene modified T cells, CAR-T cells), and cancer vaccines (particularly Dark Matter vaccines like DPV001).

While many cancers can be effectively treated, other cancers remain resistant. The development of new agents, that can be used in combination to effectively turn-on, boost, and/or maintain immune responses that can destroy cancer hold promise to improve outcomes for patients with the worst cancers.”

Quoting Earle A. Chiles Research Institute‘s post:

“Immunotherapy has transformed how we treat cancer, but T cells still face one big challenge: survival inside the tumor. Dr. Matthew Taylor, physician-researcher at Providence Cancer Institute, is addressing that with a new approach.

Introducing M3T01. This new drug targets Fas ligand (FasL), a protein that tumors use to destroy T cells. By blocking FasL, M3T01 helps protect these frontline immune cells so they can stay active longer.

Thanks to philanthropic support and institutional leadership, M3T01 is now in a phase I trial for patients with advanced or metastatic cancers, with combination studies planned for glioblastoma, head and neck and gastroesophageal cancers.

Learn more about the study and how to refer a patient.”

m3t01